Report Details:
15 Companies Covered
200 Pages
Next Generation Sequencing Market Highlights
The Next Generation Sequencing (NGS) Market reached USD 11.02 billion in 2025 and is projected to grow to USD 42.61 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.7% between 2026 and 2035.
The next generation sequencing (NGS) market refers to the market for advanced DNA sequencing technologies that enable the rapid and cost-effective analysis of large amounts of genetic material. NGS technologies have revolutionized genomics research and are widely used in various fields such as clinical diagnostics, drug discovery, agriculture, and personalized medicine.
Key Players:
MRFR recognizes the following companies as the key players in the global Next Generation Sequencing Market — Becton Eurofins Scientific (US), Illumina, Inc. (US), Genome Life Sciences (India), GenScript (US), Thermo Fisher Scientific, Inc. (US), Qiagen (Germany), PerkinElmer, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences of California, Inc. (US), Xcelris Genomics (India), and Others
Segment Analysis
The global Next Generation Sequencing Market has been segmented based Technology, Workflow and end user.
The next generation sequencing market segmentation, based on technology, includes whole exome sequencing targeted sequencing and resequencing, and whole genome sequencing. Furthermore, targeted sequencing and resequencing bifurcated into DNA-based targeted sequencing & resequencing and RNA-based targeted sequencing & resequencing. The whole exome sequencing segment held the majority share in 2024 contribution to around ~40-42% in respect to the next generation revenue. This is owing to the technological advancements that allow for the rapid sequencing of large amounts of DNA.
The next generation sequencing market segmentation, based on workflow, includes pre-sequencing, sequencing, and data analysis. Furthermore, pre-sequencing has been segmented into NGS library preparation kits, NGS semi-automated library preparation kits, NGS automated library preparation kits, and clonal amplification moreover, data analysis further segmented by type into NGS primary data analysis, NGS secondary data analysis, and NGS tertiary data analysis.
The pre-sequencing dominated the market in 2024 and is projected to be the faster-growing segment during the forecast period, 2025-2035. The sequencing is a critical step of the workflow and is a capital-intensive procedure that, in turn, accounts for a higher revenue generation. The last step in the next generation sequencing workflow is processing, analysis, and interpretation of the sequencing data generated.
Based on end user, the next generation industry has been segmented into hospitals & clinics, diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The diagnostic laboratories segment dominated the market in 2021, while academic & research institutes is projected to be the fastest-growing segment during the forecast period.
There are two types of NGS tests for clinical diagnosis, namely, laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Adopting LDTs for routine clinical diagnostics requires ease of use for laboratories and quick turnaround to ensure timely decision-making by clinicians. Both IVDs and LDT are easily reproducible, attainable, reliable, and cost-effective results in the adoption of NGS technology.
Regional Analysis
The global Next Generation Sequencing Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World . North America next generation market accounted for USD 4.19 billion in 2021 and is expected to exhibit an 18.15% CAGR during the study period. This large market share is due to developed healthcare infrastructure, increasing incidence of cancer, and increasing application of Next Generation Sequencing in precision medicine in the region.
In addition, the rise in the adoption rate of NGS platforms for analysis and diagnostics of rare diseases and for identifying therapeutic targets, the emergence of rapid and advanced sequencing technologies reduced the costs of sequencing, growing demand for NGS methodologies in genomics research, and in clinical diagnosis is further driving the market in this region.
Europe next generation market accounts for the second-largest market share due to an increasing technological advancement in sequencing, extensive use of genomics for medical applications, and increasing healthcare expenditure High-throughput sequencing, most widely considered the "next-generation" sequencing (NGS), is integrated into routine clinical practice due to the numerous technical and functional developments.
The increased technological advancement leads to the development of highly efficient next generation sequencing and, in turn, market growth. Furthermore, the Germany next generation market held the largest market share, and the France next generation market was the fastest growing market in the Europe region
Emerging economies, such as China, Japan, and India, have accepted the next generation technology due to its lower cost. The cost of sequencing in India has reduced over the years owing to factors such as advances in the field of genomics and the development of different methods and strategies for sequencing. Moreover, China next generation market held the largest market share, and the India next generation market was the fastest growing market in the Asia-Pacific region.
Key Findings of the Study
- Drug discovery and personalized medicine contributed USD 3.61 billion in 2025
- Genetic screening is advancing at a 15.3% CAGR, the highest among applications.
- North America commanded 38.9% of the Next Generation Sequencing Market in 2025
- Asia-Pacific is set to register a 15.2% CAGR from 2026 to 2035
- Europe generated USD 3.02 billion in 2025 revenue
